Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02130362 · ClinicalTrials.gov registry record
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
A clinical trial of Crohn's Disease, sponsored by AbbVie.
- Active
- Registry status
- 1,446
- Enrollment target
- 20
- Study locations
NCT02130362: Active study of Crohn's Disease, sponsored by AbbVie.
NCT02130362 is a study of Crohn's Disease that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 1,446 participants, below the 2,381-participant average among 105 other Crohn's Disease trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02130362, a study of Crohn's Disease, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- 1,446 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label.
Conditions Studied
Study Locations (20)
California
- Children's Hospital Los Angeles /ID# 141551 - Los Angeles
- Private practice: Dr. Shervin Rabizadeh /ID# 137269 - Los Angeles
- Rady Children's Hospital San Diego /ID# 140883 - San Diego
- Univ California, San Francisco /ID# 141312 - San Francisco
Massachusetts
- Tufts Medical Center /ID# 143581 - Boston
- Massachusetts General Hospital /ID# 141552 - Boston
- Boston Children's Hospital /ID# 164102 - Boston
- Duplicate_UMass Chan Medical School /ID# 148325 - Worcester
Alabama
- Univ Alabama, Birmingham CCC /ID# 146060 - Birmingham
- University of South Alabama /ID# 137255 - Mobile
Connecticut
- Connecticut Children's Medical Center - Hartford /ID# 137265 - Hartford
- Yale University School of Medicine /ID# 137257 - New Haven
Florida
- Nemours Children's Health System /ID# 148498 - Jacksonville
- University of Miami /ID# 140893 - Miami
Georgia
- Winship Cancer Institute of Emory University /ID# 144274 - Atlanta
- Children's Ctr Digestive, US /ID# 144625 - Atlanta
Arizona
- Phoenix Children's Hospital /ID# 141336 - Phoenix
Colorado
- Children's Hospital Colorado - Aurora /ID# 137261 - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,446 participants |
| Start Date | 2014-08-28 |
| Est. Completion | 2030-11 |
What the registry record for NCT02130362 still lists
NCT02130362 is an observational study that tracks outcomes without assigning an intervention. Its 1,446 participants enrollment target places it among the larger protocols in the corpus, below the 2,381-participant average among 105 other Crohn's Disease trials with a reported enrollment target (39% lower).
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02130362 names 20 study sites across 10 states, led by California, Massachusetts, Alabama.
Frequently Asked Questions
What is clinical trial NCT02130362 about?
NCT02130362 is a clinical study titled "A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)". This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in pediatric patients with moderately to severely active CD who are treated as recommended in the local product label.
What is the current status of trial NCT02130362?
This trial is currently active not recruiting. The enrollment target is 1,446 participants. The study started on 2014-08-28. Estimated completion is 2030-11.
What conditions does trial NCT02130362 study?
This clinical trial studies the following conditions: Crohn's Disease.
Who is sponsoring clinical trial NCT02130362?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02130362 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02130362's enrollment target sits among peer trials
1,446 4th of 105 higher than 102 of 105 other Crohn's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdominal Pain in Quiescent Crohn's Disease
RECRUITING · NA
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
Behavioral Therapy for Crohn's Disease
RECRUITING · NA
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
RECRUITING · Phase 4
-
Helmsley 3.0: Abbreviated MRE
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- NCT05229341 · 1,450 participants · NA
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
- NCT05910268 · 1,450 participants · NA
Peru Decentralized HIV Care
- NCT06305312 · 1,450 participants · NA
Community Services Navigation to Advance Health Equity in Breast Cancer Screening
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI